Deaths registered in 2019 in England and Wales due to dementia and Alzheimer's disease, by sex, age group, ethnicity, region and place of occurrence. Includes analysis of comorbidities.

In 2022, the mortality rate due to Alzheimer's disease was 36 deaths per 100,000 people. This statistic displays the annual Alzheimer's disease mortality rate in the United States from 2000 to 2022. Scientists believe that early detection of Alzheimer's can be the best way to prevent or slow the course of the disease. Alzheimer’s disease Alzheimer’s disease, a progressive and incurable brain disease, is among the top ten leading causes of death in the U.S. as well as worldwide. Furthermore, over the past two decades, the number of deaths due to Alzheimer’s and other dementias in the United States increased by over 140 percent. As with other dementias, Alzheimer’s commonly affects older individuals, although it can be diagnosed earlier on in life. In the United States, the majority of people with Alzheimer’s disease are over 75 years of age. Initial symptoms include difficulties in memory and mood changes, but the disease gradually progresses to impair communication and judgment, behavioral changes, and deficits in movement and motor skills, such as difficulties with swallowing, which often becomes a contributing cause of death. Care and treatment The cost of care for individuals with Alzheimer’s is expected to increase over the next couple of decades, with costs to Medicare and Medicaid expected to reach 637 billion U.S. dollars by 2050. Due to the increasing burden of Alzheimer’s and other dementias on healthcare and social systems, research into treatment and prevention is a major focus. Several major pharmaceutical companies currently have multiple drugs for Alzheimer’s treatment in various stages of development; other research is focused on identifying early brain changes associated with the disease in order to provide early diagnosis and intervention. Furthermore, personal health strategies include reducing modifiable risk factors commonly associated with cardiovascular health, such as quitting smoking, maintaining a healthy diet, and staying socially, mentally, and physically active.

Correction 21 September 2023 - We regret that an error in the number of deaths in NHS Fife in 2022 was discovered in Table 4a. An updated version of this table has now been published. This section presents information on the numbers of deaths which had an underlying cause of dementia or Alzheimer’s disease.

As of 2022, the United Kingdom had a mortality rate due to dementia of over 64 per 100,000 population, followed by the Netherlands that recorded 57.4 deaths per 100,000 population in 2022. This statistic displays the number of deaths due to dementia in selected European countries in 2022 (per 100,000 population).

Gender, age, place of death and cause(s) of death for the patients dying from Alzheimer’s disease compared to other dementia diagnoses and unspecified dementia.

IntroductionInconsistencies of reports contributes to the underreporting of Alzheimer’s disease (AD) on death certificates. Whether underreporting exists within South Carolina has not been studied.MethodsWe conducted a prospective, population-based study on a cohort of persons (N = 78,534) previously diagnosed with AD and died between 2014–2019. We linked vital records with the South Carolina Alzheimer’s Disease and Related Dementias Registry to investigate their cause of death and survival rates. Descriptive analyses calculated frequencies of demographic and health-related characteristics. Turnbull’s method estimated the survival probabilities for different subgroups of patients. Hazard ratios were computed from the Cox proportional hazards model, adjusting for the following confounding variables of age at diagnosis, education level, gender, and race.ResultsThe top immediate cause of death was Alzheimer’s disease among all racial groups, except for Native American/American Indian. More females (60.3%) were affected by AD compared to males (39.7%). There is a 25% probability of survival, beyond 5 years, after AD diagnosis. Black/African American AD patients have the smallest risk of all-cause mortality across all racial/ethnic groups (HR 0.87; 95% CI, 0.85–0.89). Individuals with lower education had a lower likelihood of mortality.ConclusionAlthough AD was not underreported in the state of South Carolina further research is needed to develop protocols around classification of deaths among those diagnosed with dementia and comorbidities, including cardiovascular disease, to ensure dementia is properly reported as we move to prevent and treat Alzheimer’s disease by 2025 and beyond.

In 2022, there were 288,436 deaths due to dementia among those aged 65 years and older in the United States. Women accounted for 193,143 of these deaths. This statistic shows the number of deaths from dementia in the U.S. among those aged 65 years and older from 2018 to 2022, by gender.

Global Dementia Mortality Share by Country (Units (Deaths)), 2023 Discover more data with ReportLinker!

Odds ratios (OR) and 95% confidence intervals (CI) are reported.

Age-standardised mortality rates, hazard ratios, and leading cause analysis exploring risk of all-cause mortality, death involving and not involving coronavirus (COVID-19) by dementia diagnosis.

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov. This visualization provides weekly data on the number of deaths by jurisdiction of occurrence and cause of death. Counts of deaths in more recent weeks can be compared with counts from earlier years to determine if the number is higher than expected. Selected causes of death are shown, based on analyses of the most prevalent comorbid conditions reported on death certificates where COVID-19 was listed as a cause of death (see https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm#Comorbidities). Cause of death counts are based on the underlying cause of death, and presented for Respiratory diseases, Circulatory diseases, Malignant neoplasms, and Alzheimer disease and dementia. Estimated numbers of deaths due to these other causes of death could represent misclassified COVID-19 deaths, or potentially could be indirectly related to COVID-19 (e.g., deaths from other causes occurring in the context of health care shortages or overburdened health care systems). Deaths with an underlying cause of death of COVID-19 are not included in these estimates of deaths due to other causes. Deaths due to external causes (i.e. injuries) or unknown causes are excluded. For more detail, see the Technical Notes.

This statistic shows the number of deaths attributed to dementia in the U.S. in 2017, by type of dementia. In that year, there were a total of 261,914 deaths in which dementia was the underlying cause. Alzheimer's disease accounted for around 121,400 of these deaths.

Gender, age, and place of death for the dementia and cancer groups.

In 2022, there were a total of 288,436 deaths among those aged 65 years and older in which dementia was the underlying cause. Around 45 percent of these deaths occurred in a nursing home or long-term care facility. This statistic shows the distribution of deaths in the U.S. with dementia as the underlying cause among those aged 65 years and older from 2018 to 2022, by location of death.

Alzheimer disease or unspecified dementia death patterns among adults with/without Down syndrome, 2005–2019.

Objective: To evaluate the risk of death in relation to incident antiepileptic drug use compared with non-use in people with Alzheimer's disease (AD) through the assessment in terms of duration of use, specific drugs and main causes of death. Methods: The MEDALZ cohort includes all Finnish persons who received a clinically verified AD diagnosis (N=70718) in 2005‒2011. Incident AED users were identified with 1-year washout period. For each incident AED user (n=5638) one non-user was matched according to sex, age and time since AD diagnosis. Analyses were conducted with Cox proportional hazards models and inverse probability of treatment weighting (IPTW). Results: Nearly 50% discontinued AEDs within six months. Compared with non-users, AED users had an increased relative risk of death (IPTW hazard ratio (HR): 1.23; 95% CI: 1.12‒1.36). This was mainly due to deaths from dementia (IPTW HR: 1.62, 95% CI: 1.42‒1.86). There was no difference in cardio- and cerebrovascular deaths (IPTW HR: 0.98, 95% CI: 0.67‒1.44). The overall mortality was highest during the first 90 days of AED use (IPTW HR: 2.40, 95% CI: 1.91‒3.03). Among users of older AEDs relative risk of death was greater compared to users of newer AED use (IPTW HR: 1.79, 95% CI: 1.52‒2.16). Conclusions: In old vulnerable population with cognitive disorder, careful consideration of AED initiation and close adverse events monitoring are needed.

Deaths of residents related to dementias including Alzheimer

🇪🇺 유럽연합